Project description
Advancing antibody-radioisotope treatment
Antibody-radioisotope combinations are a targeted therapeutic approach that delivers radioactive isotopes directly to cancer cells by attaching them to antibodies specific to tumour antigens. This method improves treatment efficacy for resistant cancers while minimising damage to surrounding healthy tissue. The EU-funded ILLUMINATE project seeks to address the isotope shortage and side effects for about 30% of patients. Researchers will enhance imaging for better treatment response insights and personalised care. They will also increase isotope production through sustainable methods to ensure availability. Overall, ILLUMINATE is expected to improve radioisotope theranostics and manufacturing.
Objective
Selective targeting of therapy with antibody-radioisotope combinations have led to major advances in treating cancers that are resistant to common therapies, such as castrate-resistant prostate cancer. Adding Lutetium-177-PSMA (Lu-177-PSMA) to standard care significantly prolongs survival. However, the increased use of Lu-177-based therapies has resulted in an increased demand for this isotope, leading to shortage risks.In addition, despite the success of Lu-177-treatment, ~30% of patients do not benefit from treatment, but do suffer from side-effects.
ILLUMINATE, will improve the availability and use of theranostics across its value chain by taking a hybrid approach: 1) Imaging capabilities will be improved by implementing novel, broadly applicable, scalable and highly effective Metabolic Magnetic Resonance Imaging (MeMRI), which are expected to give better and faster insight into treatment responses, allowing better patient stratification
and treatment personalisation; 2) The availability of Lu-177 will be fortified by improving its manufacturing process, and by developing sustainable production methods to help meet the general need for radio-isotope based therapies and increase EU autonomy. The ILLUMINATE consortium (industries Philips, NRG, Bracco, TeslaDC, Wavetronica, Lygature, SDN, EuroBioImaging, and the Univerisities of Torino, Lund, Amsterdam UMC, Klinik Essen, coordinated by UMC Utrecht) uses the example of Lu-177-PSMA as a showcase clinical trial in 150 patients for broadly applicable innovative technologies in the field of theranostics and radioisotope manufacturing for oncology.
Fields of science (EuroSciVoc)
CORDIS classifies projects with EuroSciVoc, a multilingual taxonomy of fields of science, through a semi-automatic process based on NLP techniques.
CORDIS classifies projects with EuroSciVoc, a multilingual taxonomy of fields of science, through a semi-automatic process based on NLP techniques.
You need to log in or register to use this function
Programme(s)
- HORIZON.2.1 - Health Main Programme
- HORIZON.2.1.7 - Innovative Health Initiative
Funding Scheme
HORIZON-JU-RIA - HORIZON JU Research and Innovation ActionsCoordinator
3584 CX Utrecht
Netherlands